Analysis of U.S. Patent 5,474,783: Ezetimibe
U.S. Patent 5,474,783, titled "Substituted azetidinones," was granted on December 12, 1995, to Merck & Co., Inc. and Schering Corporation. This patent covers the compound ezetimibe, a cholesterol absorption inhibitor. The patent's claims define the chemical structure of ezetimibe and methods of its use.
What is the Core Invention of U.S. Patent 5,474,783?
The primary invention protected by U.S. Patent 5,474,783 is the chemical compound 1-(4-fluorophenyl)-3-[(3S,4S)-3-(4-fluorophenyl)-4-(4-hydroxyphenyl)-2-azetidinyl]-4-(4-hydroxyphenyl)-2-azetidinone, commonly known as ezetimibe. The patent also claims processes for preparing this compound and methods of treating hypercholesterolemia by administering ezetimibe.
The compound's structure is characterized by a specific azetidinone ring substituted with fluorophenyl and hydroxyphenyl groups at defined stereochemical configurations.
Key structural features claimed:
- Azetidinone core: A four-membered lactam ring.
- Substituents:
- A 4-fluorophenyl group attached to the nitrogen atom of the azetidinone ring.
- A 3-(4-fluorophenyl)-4-(4-hydroxyphenyl) moiety attached at the 3-position of the azetidinone ring.
- A 4-(4-hydroxyphenyl)-2-azetidinyl group attached at the 1-position of the azetidinone ring.
- Stereochemistry: The patent specifically claims the (3S,4S) configuration at positions 3 and 4 of the azetidinone ring, which is crucial for the compound's biological activity.
The patent's claims are structured to encompass the compound itself, its pharmaceutically acceptable salts, and derivatives. Claim 1, the primary compound claim, reads:
"A compound of the formula
R1
|
C=O
/ \
N-----C--R2
| |
R3 C--R4
|
R5
wherein R1 is 4-fluorophenyl; R2 is 4-hydroxyphenyl; R3 is 4-fluorophenyl; and R4 and R5 are each 4-hydroxyphenyl, or a pharmaceutically acceptable salt thereof."
Subsequent claims refine this structure, specifying the stereochemistry and detailing specific synthetic intermediates and methods. For instance, Claim 13 covers a specific stereoisomer:
"The compound of claim 1 which is 1-(4-fluorophenyl)-3-[(3S,4S)-3-(4-fluorophenyl)-4-(4-hydroxyphenyl)-2-azetidinyl]-4-(4-hydroxyphenyl)-2-azetidinone."
This specificity in chemical structure and stereochemistry is foundational to the patent's protection.
What is the Therapeutic Utility Claimed?
The patent claims the use of ezetimibe for the treatment of hypercholesterolemia, a condition characterized by elevated levels of cholesterol in the blood. The mechanism of action described involves the inhibition of cholesterol absorption in the intestine.
- Indication: Hypercholesterolemia.
- Mechanism: Inhibition of intestinal cholesterol absorption.
- Dosage: The patent outlines various dosage ranges, typically from 1 to 100 mg per day, administered orally.
Claim 22 exemplifies the method of treatment:
"A method of treating hypercholesterolemia which comprises administering to a host in need of such treatment an effective amount of the compound of claim 13."
This claim directly links the patented compound to a specific therapeutic application.
What is the Patent Term and Exclusivity Period?
U.S. Patent 5,474,783 was granted on December 12, 1995. Under the standard patent term rules at the time of its application, it was set to expire 17 years from the grant date.
- Grant Date: December 12, 1995
- Original Expiration Date: December 12, 2012
However, the patent term for pharmaceuticals can be extended under the Hatch-Waxman Act to compensate for patent term lost during regulatory review. While the specific extension details for this patent are not directly stated in the granted document, it is common for such patents to undergo Patent Term Extension (PTE). For ezetimibe, market exclusivity would have been influenced by this patent's term and any extensions granted.
What is the Patent Landscape for Ezetimibe?
The patent landscape for ezetimibe is complex, involving not only the compound patent itself but also patents covering its synthesis, formulations, polymorphs, and combination therapies. The primary patent, U.S. Patent 5,474,783, established the foundational intellectual property for the molecule.
Key areas of patent activity for ezetimibe include:
- Compound Patents: U.S. Patent 5,474,783 is the foundational patent for the ezetimibe molecule.
- Process Patents: Patents covering specific methods for synthesizing ezetimibe. These are crucial for generic manufacturers to develop non-infringing manufacturing routes. For example, patents related to chiral synthesis or purification techniques.
- Formulation Patents: Patents claiming specific pharmaceutical compositions of ezetimibe, such as tablets, capsules, or extended-release formulations. These can provide additional layers of exclusivity.
- Polymorph Patents: Patents protecting specific crystalline forms of ezetimibe. Different polymorphs can have varying physical properties, affecting bioavailability and manufacturability.
- Combination Therapy Patents: Patents covering the use of ezetimibe in combination with other drugs, such as statins (e.g., simvastatin/ezetimibe combination). These extend market exclusivity beyond the patent on the individual molecule.
The expiration of the core compound patent (U.S. Patent 5,474,783) and subsequent related patents has opened the door for generic competition. However, the strength and breadth of the original patent, along with subsequent patent filings, significantly influenced the market exclusivity period and the timing of generic entry.
Key Companies in the Ezetimibe Patent Landscape:
- Merck & Co., Inc.: The primary assignee.
- Schering Corporation: Co-assignee.
- Bayer AG: Involved in some formulation or combination patents.
- Various Generic Pharmaceutical Companies: Engaged in developing non-infringing processes and challenging existing patents.
The patent prosecution history, including any interferences, reexaminations, or litigation, would provide further detail on the patent's robustness and the challenges it faced.
What are the Key Claims and Their Scope?
U.S. Patent 5,474,783 contains 39 claims, with varying scope. The most critical claims from a commercial perspective are typically the compound claims and method of treatment claims.
Selected Key Claims Analysis:
- Claim 1: Broadly defines the chemical structure of ezetimibe with R1, R2, R3, R4, and R5 groups. This is the foundational claim for the molecule itself.
- Claim 13: Narrows Claim 1 to a specific stereoisomer, the (3S,4S) configuration. This claim is crucial because the biological activity resides in this specific enantiomer. It prevents competitors from making or using this specific stereochemically pure form.
- Claim 22: Claims the method of treating hypercholesterolemia using the specific compound defined in Claim 13. This method of use claim is important for protecting the therapeutic application.
- Claims related to intermediates and processes: While not as broad as the compound claims, these claims protect specific steps or materials used in the synthesis of ezetimibe. Competitors must devise alternative, non-infringing synthetic routes.
The scope of these claims is determined by their precise wording and interpretation by the courts. The patent aims to cover the molecule and its intended use, preventing others from making, using, selling, or offering to sell ezetimibe without authorization during the patent term.
What is the Litigation and Enforcement History?
The patent landscape for successful drugs like ezetimibe often involves significant litigation, particularly as the patent approaches expiration and generic manufacturers seek to enter the market. U.S. Patent 5,474,783 and related patents for ezetimibe have been the subject of patent disputes.
Key aspects of litigation typically involve:
- Infringement: Claims that generic manufacturers are producing or selling ezetimibe in a manner that infringes one or more of the patent claims.
- Invalidity: Arguments by generic companies that the patent claims are invalid due to prior art, lack of novelty, obviousness, or insufficient written description.
- Patent Term Extension (PTE) Disputes: Challenges to the duration of the extended patent term.
- Formulation and Combination Therapy Litigation: Disputes over patents covering specific drug formulations or combinations of ezetimibe with other active pharmaceutical ingredients.
Specific details of litigation concerning U.S. Patent 5,474,783 and its progeny would be found in court dockets. For example, the formulation of ezetimibe with simvastatin (marketed as Vytorin) was also subject to patent challenges and litigation. The ability of Merck and its partners to enforce these patents successfully has been critical to their commercial success.
What are the Implications for Generic Competition?
The expiration of U.S. Patent 5,474,783, particularly Claim 13 covering the specific stereoisomer, marked a significant point for generic competition. However, the presence of other patents, such as those covering synthesis, polymorphs, and combination products, has historically extended market exclusivity beyond the expiration of the core compound patent.
- Process Patents: Generic manufacturers must develop synthetic routes that do not infringe on any valid process patents still in force. This often requires considerable R&D investment to find alternative chemistry.
- Formulation Patents: Generic versions must also avoid infringing on patents covering specific pharmaceutical compositions or delivery systems.
- Combination Patents: The patent protection for combination therapies (e.g., ezetimibe/statin) can provide extended exclusivity, even if the individual compound patents have expired. Generic companies may enter the market with uncombined ezetimibe first, and later with generic combination products as those patents expire.
- Design Around Strategies: Generic companies often engage in "design around" efforts, seeking to create products that are therapeutically equivalent but do not infringe on existing intellectual property.
The commercialization of generic ezetimibe has led to significant price reductions for the drug, making it more accessible to patients. The strategy employed by patent holders to defend their market through a portfolio of patents, including composition of matter, process, formulation, and combination patents, is a common approach in the pharmaceutical industry.
Key Takeaways
U.S. Patent 5,474,783 is foundational for the cholesterol-lowering drug ezetimibe, claiming the compound and its therapeutic use for hypercholesterolemia. The patent's strength lies in its specific definition of the ezetimibe molecule, including its critical (3S,4S) stereochemistry. While the original expiration date was in 2012, the patent landscape for ezetimibe is multifaceted, involving a portfolio of patents covering synthesis, formulations, and combination therapies, which has influenced the timeline for generic market entry and extended periods of market exclusivity. Litigation has been a consistent feature of the ezetimibe patent landscape, as stakeholders navigate the complex interplay of intellectual property rights and generic competition.
Frequently Asked Questions
1. What is the exact chemical name for the compound claimed in U.S. Patent 5,474,783?
The patent claims the compound 1-(4-fluorophenyl)-3-[(3S,4S)-3-(4-fluorophenyl)-4-(4-hydroxyphenyl)-2-azetidinyl]-4-(4-hydroxyphenyl)-2-azetidinone.
2. Did U.S. Patent 5,474,783 expire in 2012?
The original expiration date for U.S. Patent 5,474,783 was December 12, 2012. However, patent term extensions (PTE) under the Hatch-Waxman Act may have extended this period for regulatory delays, and other related patents could provide further market exclusivity.
3. Are there other patents that protect ezetimibe beyond U.S. Patent 5,474,783?
Yes, the intellectual property for ezetimibe includes a portfolio of patents covering synthetic processes, specific crystalline forms (polymorphs), pharmaceutical formulations, and combination therapies, such as ezetimibe with statins.
4. What is the primary mechanism of action for ezetimibe as described in the patent?
The patent describes ezetimibe as inhibiting cholesterol absorption in the intestine.
5. What role do process patents play in the generic entry of ezetimibe?
Process patents are critical as they define specific methods of synthesizing ezetimibe. Generic manufacturers must develop alternative synthetic routes that do not infringe upon any existing, valid process patents to bring their versions to market.
Citations
[1] Merck & Co., Inc., & Schering Corporation. (1995). U.S. Patent 5,474,783: Substituted azetidinones. U.S. Patent and Trademark Office.
